59311-67-0

Basic information

• Product Name: 2-(3-THIENYL)ETHANAMINE
• Synonyms: 2-(3-THIENYL)ETHANAMINE;2-THIOPHEN-3-YL-ETHYLAMINE;RARECHEM AL BW 0259;2-(3-Thienyl)ethylamine;3-Thiopheneethanamine;Thiophene-3-Ethylamine;2-(thien-3-yl)-ethylaMine;2-(Thiophen-3-yl)ethanaMine HCl
• CAS NO: 59311-67-0
• Molecular Formula: C₆H₉NS
• Molecular Weight: 127.21
• Product Categories: Thiophene;CHIRAL CHEMICALS
• Mol File: 59311-67-0.mol
• Article Data: 17

Chemical Properties

• Boiling Point: 203.8 °C at 760 mmHg
• Flash Point: 77.1 °C
• Appearance: /
• Density: 1.102 g/cm³
• Vapor Pressure: 0.272mmHg at 25°C
• Refractive Index: 1.567
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 10.02±0.10(Predicted)
• CAS DataBase Reference: 2-(3-THIENYL)ETHANAMINE(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(3-THIENYL)ETHANAMINE(59311-67-0)
• EPA Substance Registry System: 2-(3-THIENYL)ETHANAMINE(59311-67-0)

Safety Data

• Hazardous Substances Data: 59311-67-0(Hazardous Substances Data)

Usage

Description

2-(3-Thienyl)ethanamine, also known as 3-Thienylethylamine, is a chemical compound belonging to the class of aromatic amines. It is a derivative of thiofuran, characterized by its thienyl group, which consists of a five-membered sulfur-containing ring. 2-(3-THIENYL)ETHANAMINE has potential applications in pharmaceutical and medical research due to its ability to interact with biological systems through its amine functional group. The thienyl group may also confer specific biological activities that could be of interest for medicinal chemistry. Its synthesis and structural properties are of interest to researchers studying the potential pharmaceutical and biological activities of 2-(3-Thienyl)ethanamine.

Uses

Used in Pharmaceutical Industry:
2-(3-Thienyl)ethanamine is used as a pharmaceutical intermediate for the development of various drugs. Its amine functional group allows for the formation of various chemical bonds and interactions with biological systems, making it a valuable component in the synthesis of pharmaceutical compounds.
Used in Medical Research:
2-(3-Thienyl)ethanamine is used as a research compound in the field of medical research. Its unique structure and potential biological activities make it an interesting candidate for studying its effects on various biological processes and its potential use in the development of new therapeutic agents.
Used in Medicinal Chemistry:
2-(3-Thienyl)ethanamine is used as a building block in the design and synthesis of novel compounds with potential medicinal properties. The thienyl group may confer specific biological activities that could be exploited for the development of new drugs with unique mechanisms of action.

InChI:InChI=1/C6H9NS/c7-3-1-6-2-4-8-5-6/h2,4-5H,1,3,7H2

Upstream product

• 13781-53-8 (thiophen-3-yl)acetonitrile 
• 498-62-4 3-thiophene carboxaldehyde 
• 75-52-5 nitromethane 
• 26415-26-9 [3]thienylmethyl-malonic acid 
• 16378-06-6 3-(3-thienyl)propanoic acid 
• 34846-44-1 3-Bromomethylthiophene 
• 26359-23-9 3-thienylpropionic acid chloride 
• 110143-52-7 3-[(E)-2-nitroethenyl]thiophene 
• 616-44-4 3-Methylthiophene 
• 26415-25-8 3-thiophen-3-yl methyl malonic acid diethyl ester 

Downstream Products

• 188471-59-2 3-Hydroxy-2-(2-thiophen-3-yl-ethyl)-2,3-dihydro-isoindol-1-one 
• 188471-62-7 3-Ethyl-3-hydroxy-2-(2-thiophen-3-yl-ethyl)-2,3-dihydro-isoindol-1-one 
• 188471-65-0 3-Hydroxy-3-phenyl-2-(2-thiophen-3-yl-ethyl)-2,3-dihydro-isoindol-1-one 
• 121449-96-5 2-(7-Phenyl-4,7-dihydro-5H-thieno[2,3-c]pyridin-6-yl)-ethanol 
• 121433-64-5 10-phenyl-4,5,6,7,8,10-hexahydrothieno<3,2-g><1,4>oxazonine-6-carbonitrile 
• 1190130-50-7 7-(4-chlorobenzyl)-7-trifluoromethyl-4,5,6,7-tetrahydrothieno[2,3-c]pyridine 
• 1304613-03-3 C₁₃H₁₂INOS 

Relevant articles and documents

Unified Synthesis of Polycyclic Alkaloids by Complementary Carbonyl Activation**

A complementary dual carbonyl activation strategy for the synthesis of polycyclic alkaloids has been developed. Successful applications include the synthesis of tetracyclic alkaloids harmalanine and harmalacinine, pentacyclic indoloquinolizidine alkaloid nortetoyobyrine, and octacyclic β-carboline alkaloid peganumine A. The latter synthesis features a protecting-group-free assembly and an asymmetric disulfonimide-catalyzed cyclization. Furthermore, formal syntheses of hirsutine, deplancheine, 10-desbromoarborescidine A, and oxindole alkaloids rhynchophylline and isorhynchophylline have been achieved. Finally, a concise synthesis of berberine alkaloid ilicifoline B was completed.

Reaction of Diisobutylaluminum Borohydride, a Binary Hydride, with Selected Organic Compounds Containing Representative Functional Groups

The binary hydride, diisobutylaluminum borohydride [(iBu)2AlBH4], synthesized from diisobutylaluminum hydride (DIBAL) and borane dimethyl sulfide (BMS) has shown great potential in reducing a variety of organic functional groups. This unique binary hydride, (iBu)2AlBH4, is readily synthesized, versatile, and simple to use. Aldehydes, ketones, esters, and epoxides are reduced very fast to the corresponding alcohols in essentially quantitative yields. This binary hydride can reduce tertiary amides rapidly to the corresponding amines at 25 °C in an efficient manner. Furthermore, nitriles are converted into the corresponding amines in essentially quantitative yields. These reactions occur under ambient conditions and are completed in an hour or less. The reduction products are isolated through a simple acid-base extraction and without the use of column chromatography. Further investigation showed that (iBu)2AlBH4 has the potential to be a selective hydride donor as shown through a series of competitive reactions. Similarities and differences between (iBu)2AlBH4, DIBAL, and BMS are discussed.

Design, synthesis and evaluation of novel N-phenylbutanamide derivatives as KCNQ openers for the treatment of epilepsy

KCNQ (Kv7) has emerged as a validated target for the development of novel anti-epileptic drugs. In this paper, a series of novel N-phenylbutanamide derivatives were designed, synthesized and evaluated as KCNQ openers for the treatment of epilepsy. These compounds were evaluated for their KCNQ opening activity in vitro and in vivo. Several compounds were found to be potent KCNQ openers. Compound 1 with favorable in vitro activity was submitted to evaluation in vivo. Results showed that compound 1 owned significant anti-convulsant activity with no adverse effects. It was also found to posses favorable pharmacokinetic profiles in rat. This research may provide novel potent compounds for the discovery of KCNQ openers in treating epilepsy.